Fair Value of Financial Instruments - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2025	Jun. 30, 2025	Sep. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Apr. 01, 2025	Dec. 31, 2024	Jun. 15, 2024
Fair Value, Option, Quantitative Disclosures [Line Items]
Unrealized gain (loss) on investment in equity securities				$ (289)	$ 38,167
Business combination contingent consideration liability		$ 43,042		43,042
Progenics
Fair Value, Option, Quantitative Disclosures [Line Items]
Payments for prior acquisition				85,000
Business combination contingent consideration liability		0		0			$ 0
Progenics | Net Sales Targets for Azedra
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high		70,000		70,000
Progenics | 1095 Commercialization [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high		5,000		5,000
Progenics | 1404 Commercialization Milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high		$ 10,000		$ 10,000
Evergreen Theragnostics
Fair Value, Option, Quantitative Disclosures [Line Items]
Business combination contingent consideration liability						$ 25,000
Evergreen Theragnostics | Additional Remaining Payments
Fair Value, Option, Quantitative Disclosures [Line Items]
Business combination contingent consideration liability						$ 727,500
Radiopharm Theranostics Limited
Fair Value, Option, Quantitative Disclosures [Line Items]
Shares owned (in shares)	133,333,333	282,958,513	149,625,180	282,958,513			149,625,180
Investment owned, fair value		$ 4,100		$ 4,100
Share price (in dollars per share)	$ 0.04	$ 0.01	$ 0.03	$ 0.01
Unrealized gain (loss) on investment in equity securities		$ (800)		$ (3,300)
Purchase amount in investment in equity securities	$ 5,000		$ 5,000
Perspective Therapeutics, Inc
Fair Value, Option, Quantitative Disclosures [Line Items]
Shares owned (in shares)		11,677,339		11,677,339				11,677,339
Investment owned, fair value		$ 40,200		$ 40,200
Share price (in dollars per share)		$ 3.44		$ 3.44
Unrealized gain (loss) on investment in equity securities		$ 15,300		$ 2,900